Z
Zephyr AI
The world's most cutting-edge algorithms for advancing human health
About Zephyr AI
Zephyr AI is a startup operating in the healthcare sector, specifically in the fields of Oncology, Obesity, and Diabetes. The company uses real-world data to transform precision medicine, aiming to optimize patient outcomes. Their business model revolves around aligning the interests of pharmaceutical companies, healthcare providers, and insurance payers.
Read full description
Zephyr AI integrates advanced machine learning technology with strategic healthcare partnerships to enhance personalized care. They have developed proprietary algorithms to extract biological signals and actionable insights from real-world data. This data-driven approach allows them to validate these insights retrospectively.
The company has access to one of the most extensive multi-modal clinicogenomics datasets globally, which puts them in a unique position to capitalize on recent regulatory guidelines. These guidelines provide a framework for using real-world evidence in the development and approval of medical products.
Zephyr AI also emphasizes the importance of transparency in healthcare decision-making. Their technology not only predicts but also explains the biological mechanisms and clinical features contributing to these predictions. This approach supports the interpretability of every insight, making their algorithms more understandable and trustworthy.
The company generates revenue by providing their platform and services to pharmaceutical companies, healthcare providers, and insurance payers. They help these entities to improve patient outcomes, reduce costs, and make more informed decisions based on real-world data and insights.
At a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- McLean, United States
- Employees
- 50
- Open positions
- None listed
- Dealroom signal
- 85.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Core AI, Precision Medicine, Biotech and Pharma, MLops, AI Drug Discovery, Techbio
- Technology
- Artificial Intelligence, Machine Learning
- Business model
- SaaS
- Client focus
- b2b
- Investment activity
- 1 company, latest Aug 2025
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Mar 2024 | $111M | $444M | Eli Lilly · Revolution · EPIQ Capital Group | ↗ |
| SEEDOther financing | Mar 2022 | $19M | $74M | Allen Chao · Roger W. Ferguson · Steve Oristaglio · BoxGroup | ↗ |
Growth signals
Latest recorded traffic for Zephyr AI is 6.3K monthly website visits, up 18.9% over the last three months. Zephyr AI's team grew 6.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed9 investors entered at this stage
- LILerner Investments
Allen Chao- RFRoger W. Ferguson
- SOSteve Oristaglio
BoxGroup
AME Cloud Ventures
Verily
MedStar Health- MHM-Cor Holdings
Series A3 investors entered at this stage
Eli Lilly
Revolution
EPIQ Capital Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Zephyr AI on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Zephyr AI’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







